Biotechnology News and Research

RSS

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

The study carried out by researchers from the Centre for Plant Biotechnology and Genomics along with the Allergy Department of the Hospital Infantil Universitario Niño Jesús of Madrid have shown that, most of the children that received this new oral immunotherapy treatment were able to eat 100 grams of wheat bread without side effects. This result has overcome the risk of accidental ingestion by patients with this allergy. This research could be the basis for large clinical trials with more patients with the aim of assessing the therapeutic benefit of this new approach.

13 Jan 2015

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc., the human health information technology and health care company, today announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete.

12 Jan 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies.

11 Jan 2015

Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

This week 23andMe (a genetic testing company) and Genentech (medical research company of the Roche Group) agreed a collaboration to undertake whole genome sequencing for 3,000 patients with Parkinson’s disease. The genetic information will be collected by 23andMe and used by Genentech to identify new therapeutic targets for treating Parkinson’s disease.

9 Jan 2015

DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.

9 Jan 2015

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

8 Jan 2015

Findings could accelerate development of prebiotic medicines for bowel problems, autoimmune diseases

Bacteria that have evolved to eat their way through yeast in the human gut could inform the development of new treatments for people suffering from bowel diseases.

8 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

LSNE's Harvey Road facility receives approval to manufacture drug product for US distribution

Lyophilization Services of New England, Inc. announced today that following an FDA Pre-Approval Inspection (PAI) in November 2014, their Harvey Road manufacturing site has received approval to manufacture commercial drug product for US distribution.

7 Jan 2015

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

6 Jan 2015

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

Johnson & Johnson today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies.

6 Jan 2015

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem.

6 Jan 2015

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.

5 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101.

31 Dec 2014

Tikcro enters into research and license agreement with Yeda

Tikcro Technologies Ltd. today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel.

30 Dec 2014

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.

29 Dec 2014

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

25 Dec 2014

Soligenix closes previously announced registered public offering

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.

25 Dec 2014

Biotechnology News and Research

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

DiaCarta raises $8 million in Series A financing from BVCF

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

Findings could accelerate development of prebiotic medicines for bowel problems, autoimmune diseases

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

LSNE's Harvey Road facility receives approval to manufacture drug product for US distribution

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

BrainStorm's phase 2a ALS study meets primary endpoint

TxCell announces further enhancement to development of Ovasave for IBD treatment

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Tikcro enters into research and license agreement with Yeda

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Soligenix closes previously announced registered public offering

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News